AVM Biotechnology Announces Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Dosed with AVM0703 at major Cancer Centers in USA
SEATTLE, April 7, 2021 /PRNewswire/ — AVM Biotechnology announced today that the first cohort has been fully enrolled in their clinical study (NCT04329728 “The WWRD Study”). All three patients had failed multiple prior therapies, and one had failed two transplants. These patients are…
Comments Off on AVM Biotechnology Announces Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Dosed with AVM0703 at major Cancer Centers in USA